Bepotastine besilate OD tablets suppress nasal symptoms caused by Japanese cedar pollen exposure in an artificial exposure chamber (OHIO Chamber).
OBJECTIVE
To investigate the efficacy and safety of bepotastine, we conducted a randomized, investigator-blind, placebo-controlled and parallel study to evaluate the allergic symptoms and the cognitive function of the subjects with Japanese cedar (JC) pollinosis in response to JC pollen exposure in an artificial exposure chamber.


METHODS
Twenty-four volunteers with JC pollinosis were enrolled in this study. The subjects were randomly divided into two groups: a bepotastine group and a placebo group (12 subjects each). Subjects received either a 10-mg bepotastine OD (orally disintegrating) tablet or a placebo 10 min before entering the chamber for a 3-h exposure. The nasal and ocular symptoms were evaluated by each patient at regular intervals. The amount of nasal discharge was measured and the number of sneezes recorded. To evaluate the cognitive function, a digit cancellation test (D-CAT), in which the subjects have to eliminate certain numbers within a fixed time, was conducted.


RESULTS
Twelve subjects in the placebo group developed nasal and/or ocular symptoms, whereas six subjects in the bepotastine group showed none of the symptoms during exposure. Mean secretion weights and number of sneezes were significantly lower in the bepotastine group than in the placebo group. In D-CAT, no deterioration of work performance was observed in the bepotastine group. No adverse effects were observed in either group.


CONCLUSIONS
Bepotastine treatment is effective and well tolerated in patients with allergen-induced symptoms exposed to JC pollen in an exposure chamber.
Hashiguchi
Kazuhiro
K
Kitasato Institute Hospital, Department of Otolaryngology, Tokyo, Japan. hashiguc@insti.kitasato-u.ac.jp
Tang
Huaipeng
H
Fujita
Toshio
T
Suematsu
Kiyochika
K
Gotoh
Minoru
M
Okubo
Kimihiro
K
D000284:Administration, Oral; D000393:Air Pollutants / Q000276:immunology*; D000485:Allergens / Q000276:immunology*; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D001273:Atmosphere Exposure Chambers; D003071:Cognition / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D017817:Nasal Lavage Fluid / Q000276:immunology; D009297:Nasal Mucosa / Q000187:drug effects / Q000276:immunology; D010880:Piperidines / Q000627:therapeutic use*; D011058:Pollen / Q000276:immunology*; D011725:Pyridines / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology / Q000517:prevention & control* / Q000523:psychology; D016037:Single-Blind Method; D013607:Tablets
D000393:Air Pollutants; D000485:Allergens; D018926:Anti-Allergic Agents; D010880:Piperidines; D011725:Pyridines; D013607:Tablets; C511534:bepotastine besilate